Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735631 | 0.88 | HDAC2 (0.47) | ATMALDH1A1HPGDL3MBTL1KDM4E | |
| SCHEMBL1734622 | 0.88 | LMNA (0.40) | ALDH1A1MAPTHPGDL3MBTL1MAPK1 | |
| SCHEMBL1734620 | 0.88 | LMNA (0.40) | ALDH1A1MAPTHPGDL3MBTL1MAPK1 | |
| SCHEMBL1734646 | 0.87 | LMNA (0.41) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL1736746 | 0.84 | LMNA (0.43) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL1736745 | 0.84 | LMNA (0.43) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL1735689 | 0.81 | CHRM4 (0.44) | ALDH1A1MAPTHPGDL3MBTL1MAPK1 | |
| SCHEMBL1734700 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL1734702 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL1734689 | 0.78 | CPT2 (0.51) | ATMALDH1A1MAPTHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2142533-A1 | IMIDAZOLIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2008119657-A1 | IMIDAZOLIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | claimed |
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-2142533-A1 | IMIDAZOLIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008119657-A1 | IMIDAZOLIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | NR1H2, NR1H3, NR1I2 | ATM 1524/4885P2RY12 2096/4885ALDH1A1 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.